Prognostic implications of HIF-1α expression in anal squamous cell carcinoma treated with intensity-modulated radiotherapy (IMRT)
-
Published:2024-11
Issue:
Volume:49
Page:100853
-
ISSN:2405-6308
-
Container-title:Clinical and Translational Radiation Oncology
-
language:en
-
Short-container-title:Clinical and Translational Radiation Oncology
Author:
Mohamed Ahmed Allam,
Eble Michael J.ORCID,
Dahl EdgarORCID,
Jonigk DannyORCID,
Warkentin Svetlana
Reference35 articles.
1. Mignozzi S, Santucci C, Malvezzi M, Levi F, Vecchia C La, Negri E. Global trends in anal cancer incidence and mortality. 2023 [cited 2024 May 21]; Available from: www.eurjcancerprev.com.
2. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial;James;Lancet Oncol,2013
3. RTOG 0529: a phase II evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal;Kachnic;Int J Radiat Oncol Biol Phys,2013
4. Abhishek A, Kataria T, Gupta D, Basu T, Bisht S, Goyal S, et al. The development of an umbrella trial (PLATO) to address radiation therapy dose questions in the locoregional management of squamous cell carcinoma of the anus. Int J Radiat Oncol Biol Phys [Internet]. 2016 Oct 1 [cited 2022 Aug 10];96(2):E164–5. Available from: http://www.redjournal.org/article/S0360301616313323/fulltext.
5. Hypoxia in head and neck squamous cell carcinoma;Li;ISRN Otolaryngol,2012